6533b871fe1ef96bd12d0f6f
RESEARCH PRODUCT
Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome).
L GradoniS. ScottiAngela MaistoElio CastagnolaRobert N. DavidsonD. Di CaprioR. PempinelloGiovanni Battista GaetaL. Di MartinoRaffaella GiacchinoMarina GramicciaRobert J. WilkinsonAntonio CascioA. D. M. Brycesonsubject
Microbiology (medical)AdultMalemedicine.medical_specialtyAntifungal AgentsAdolescentmedicine.medical_treatmentGastroenterologyDrug Administration ScheduleleishmanisisInternal medicineAmphotericin BAmphotericin BMedicinevisceral leishmaniasisAnimalsHumansLeishmania infantumAdverse effectChildChemotherapyDrug Carriersbiologybusiness.industryInfantLeishmaniasisMiddle Agedmedicine.diseasebiology.organism_classificationSurgeryInfectious DiseasesVisceral leishmaniasisTreatment OutcomeTotal doseChild PreschoolLiposomesLeishmaniasis VisceralLiposomal amphotericinFemaleLeishmania infantumbusinessmedicine.drugdescription
We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommended a total dose of AmBisome of > or = 20 mg/kg, given in > or = 5 doses of 3-4 mg/kg over > or = 10 days.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1996-06-01 | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |